Clinical trials: Mild Neurocognitive Disorder
Alzheimer's Disease
A Non-drug Methods Study in Participants With Alzheimer's Disease
This study will investigate the volume, function and composition of the brain using magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning technology in participants with memory complaints or early signs…
- Trial name
- NCT01459016
- Testing
- PET scan using florbetapir, MRI Scan
- Where
- 16 sites in France
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Dementia
Semantic Memory, Financial Capacity, and Brain Perfusion in Mild Cognitive Impairment (MCI) (CASL)
Alzheimer's disease (AD) often manifests as a memory disorder before dementia develops. Dementia is considered to be present when a person can no longer handle complex activities of daily living, such as managing finances.
- Trial name
- CASL (NCT00880555)
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Mild Cognitive Impairment
Rhythmic Light Therapy for Alzheimer's Disease Patients
The investigator will investigate how light delivering 40 hertz (Hz) affects subjective sleep and cognition in a controlled laboratory study.
- Trial name
- NCT05015478
- Testing
- Tailored Rhythmic Lighting Intervention
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alzheimer's Disease
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
This is a study to evaluate the safety and tolerability of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01369225
- Testing
- AAB-003 (PF-05236812)
- Where
- 21 sites in United States, South Korea
- Volunteers
- 52 people
- Sponsor
- Pfizer
Alzheimer Disease
A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD
The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813.
- Trial name
- NCT02624778
- Testing
- LY3002813
- Where
- 9 sites in United States, Japan
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of…
- Trial name
- NCT00506415
- Testing
- Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2
- Where
- 145 sites in United States, Canada and 5 more
- Volunteers
- 1,584 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease
Study Evaluating Bapineuzumab In Alzheimer Disease Subjects
The study will evaluate the safety and effectiveness of bapineuzumab for the treatment of mild to moderate Alzheimer disease. Subjects will be in the study for six months and will receive subcutaneous injections once per week.
- Trial name
- NCT00663026
- Testing
- bapineuzumab
- Where
- 17 sites in United States
- Volunteers
- 79 people
- Sponsor
- Pfizer
Parkinson Disease, Mild Cognitive Impairment
Mild Cognitive Impairment and Endurance Exercise in Parkinson's Disease
The overall objective of this study is to determine how high intensity endurance exercise affects both cognition and the signs and symptoms of Parkinson's disease as well as if certain brain structures and functions also change…
- Trial name
- NCT03542474
- Testing
- High Intensity Endurance Exercise
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwestern University
Cognitive Decline, Cardiovascular Diseases
Lifestyle Physical Activity and Cognitive Training Interventions
Older women with cardiovascular disease (CVD) are at greater risk for memory loss, an important public health issue due to the negative effects to quality of life and health care costs.
- Conditions
- Cognitive Decline, Cardiovascular Diseases, Cognitive Dysfunction, Cognitive Impairment
- Trial name
- MindMoves (NCT04556305)
- Testing
- Mind, Move
- Where
- United States
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Mild Cognitive Impairment
Cognitive Training and Practice Effects in Mild Cognitive Impairment
The current study will test the effectiveness of a computerized cognitive training program on auditory memory and attention in patients with mild cognitive impairment.
- Trial name
- NCT02301546
- Testing
- computerized cognitive exercises
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- University of Utah
Alzheimer's Disease, Mild Cognitive Impairment
Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
To Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]flutemetamol Positron Emission Tomography (PET) Images.
- Trial name
- NCT01672827
- Testing
- [18F]Flutemetamol
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Mild Cognitive Impairment, Herpes Simplex 1
Valacyclovir for Mild Cognitive Impairment
Anti-viral treatment in Mild Cognitive Impairment (MCI) is a Phase II, placebo-controlled, 52-week trial using oral valacyclovir 4 g/day in 50 HSV seropositive, AD biomarker-positive, amnestic mild cognitive impairment (MCI)…
- Conditions
- Mild Cognitive Impairment, Herpes Simplex 1, Herpes Simplex 2
- Trial name
- VALMCI (NCT04710030)
- Testing
- Valacyclovir hydrochloride 500mg caplet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- New York State Psychiatric Institute
Alzheimer Disease
Study of BHV-4157 in Alzheimer's Disease
Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, were administered orally once daily.
- Trial name
- T2 Protect AD (NCT03605667)
- Testing
- troriluzole
- Where
- 44 sites in United States
- Volunteers
- 350 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Mild Cognitive Impairment
Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
Odor identification deficits, which are a result of early Alzheimer's Disease (AD) pathology in the olfactory bulb and tract as well as olfactory projection areas in the medial temporal lobe (entorhinal and piriform cortex and…
- Trial name
- NCT01845636
- Testing
- Donepezil, Atropine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- New York State Psychiatric Institute
Cognitive Dysfunction, Dementia, Mild
FitMi AD Home Therapy for Individuals With MCI or Mild Dementia Due to Alzheimer's Disease
This study will investigate the efficacy of a newly developed exercise device (FitMi AD) for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease.
- Trial name
- NCT05504811
- Testing
- FitMi AD, Conventional exercise program
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Flint Rehabilitation Devices, LLC
Lewy Body Dementia
A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
- Trial name
- PRESENCE (NCT03305809)
- Testing
- LY3154207
- Where
- 77 sites in United States, Canada and 1 more
- Volunteers
- 344 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD.
- Trial name
- NCT02423200
- Testing
- VX-745
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc